Literature DB >> 20964352

Targeted imaging and therapy of brain cancer using theranostic nanoparticles.

Mahaveer Swaroop Bhojani1, Marcian Van Dort, Alnawaz Rehemtulla, Brian D Ross.   

Abstract

The past decade has seen momentous development in brain cancer research in terms of novel imaging-assisted surgeries, molecularly targeted drug-based treatment regimens or adjuvant therapies and in our understanding of molecular footprints of initiation and progression of malignancy. However, mortality due to brain cancer has essentially remained unchanged in the last three decades. Thus, paradigm-changing diagnostic and therapeutic reagents are urgently needed. Nanotheranostic platforms are powerful tools for imaging and treatment of cancer. Multifunctionality of these nanovehicles offers a number of advantages over conventional agents. These include targeting to a diseased site thereby minimizing systemic toxicity, the ability to solubilize hydrophobic or labile drugs leading to improved pharmacokinetics and their potential to image, treat and predict therapeutic response. In this article, we will discuss the application of newer theranostic nanoparticles in targeted brain cancer imaging and treatment.

Entities:  

Mesh:

Year:  2010        PMID: 20964352      PMCID: PMC3291122          DOI: 10.1021/mp100298r

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  77 in total

1.  Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1998-04-06       Impact factor: 15.470

Review 2.  Poloxamers and poloxamines in nanoparticle engineering and experimental medicine.

Authors:  S M Moghimi; A C Hunter
Journal:  Trends Biotechnol       Date:  2000-10       Impact factor: 19.536

Review 3.  Bispecific antibodies in cancer therapy.

Authors:  D M Segal; G J Weiner; L M Weiner
Journal:  Curr Opin Immunol       Date:  1999-10       Impact factor: 7.486

4.  A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo.

Authors:  Kimmo Porkka; Pirjo Laakkonen; Jason A Hoffman; Michele Bernasconi; Erkki Ruoslahti
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

5.  A multi-institutional phase II study of BMS-182248-01 (BR96-doxorubicin conjugate) administered every 21 days in patients with advanced gastric adenocarcinoma.

Authors:  J A Ajani; D P Kelsen; D Haller; K Hargraves; D Healey
Journal:  Cancer J       Date:  2000 Mar-Apr       Impact factor: 3.360

Review 6.  Mylotarg: antibody-targeted chemotherapy comes of age.

Authors:  E L Sievers; M Linenberger
Journal:  Curr Opin Oncol       Date:  2001-11       Impact factor: 3.645

Review 7.  Transport of molecules, particles, and cells in solid tumors.

Authors:  R K Jain
Journal:  Annu Rev Biomed Eng       Date:  1999       Impact factor: 9.590

8.  Expression of Fas system-related genes in the testis during development and after toxicant exposure.

Authors:  K Boekelheide; J Lee; E B Shipp; J H Richburg; G Li
Journal:  Toxicol Lett       Date:  1998-12-28       Impact factor: 4.372

Review 9.  Nanoparticles in cancer therapy and diagnosis.

Authors:  Irène Brigger; Catherine Dubernet; Patrick Couvreur
Journal:  Adv Drug Deliv Rev       Date:  2002-09-13       Impact factor: 15.470

10.  Late cognitive and radiographic changes related to radiotherapy: initial prospective findings.

Authors:  C L Armstrong; J V Hunter; G E Ledakis; B Cohen; E M Tallent; B H Goldstein; Z Tochner; R Lustig; K D Judy; A Pruitt; J E Mollman; E M Stanczak; M Y Jo; T L Than; P Phillips
Journal:  Neurology       Date:  2002-07-09       Impact factor: 9.910

View more
  25 in total

Review 1.  Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates.

Authors:  Xiao-Xiang Zhang; Henry S Eden; Xiaoyuan Chen
Journal:  J Control Release       Date:  2011-10-26       Impact factor: 9.776

Review 2.  Cancer theranostics: the rise of targeted magnetic nanoparticles.

Authors:  Adam J Cole; Victor C Yang; Allan E David
Journal:  Trends Biotechnol       Date:  2011-04-12       Impact factor: 19.536

Review 3.  Assessing the barriers to image-guided drug delivery.

Authors:  Gregory M Lanza; Chrit Moonen; James R Baker; Esther Chang; Zheng Cheng; Piotr Grodzinski; Katherine Ferrara; Kullervo Hynynen; Gary Kelloff; Yong-Eun Koo Lee; Anil K Patri; David Sept; Jan E Schnitzer; Bradford J Wood; Miqin Zhang; Gang Zheng; Keyvan Farahani
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2013-10-31

4.  TRAIL conjugated to nanoparticles exhibits increased anti-tumor activities in glioma cells and glioma stem cells in vitro and in vivo.

Authors:  Benny Perlstein; Susan A Finniss; Cathie Miller; Hana Okhrimenko; Gila Kazimirsky; Simona Cazacu; Hae Kyung Lee; Nancy Lemke; Shlomit Brodie; Felix Umansky; Sandra A Rempel; Mark Rosenblum; Tom Mikklesen; Shlomo Margel; Chaya Brodie
Journal:  Neuro Oncol       Date:  2012-11-08       Impact factor: 12.300

5.  Radiation-induced tumor neoantigens: imaging and therapeutic implications.

Authors:  Christopher D Corso; Arif N Ali; Roberto Diaz
Journal:  Am J Cancer Res       Date:  2011-01-25       Impact factor: 6.166

6.  Multifunctional nanoemulsion platform for imaging guided therapy evaluated in experimental cancer.

Authors:  Anita Gianella; Peter A Jarzyna; Venkatesh Mani; Sarayu Ramachandran; Claudia Calcagno; Jun Tang; Benjamin Kann; Wouter J R Dijk; Victor L Thijssen; Arjan W Griffioen; Gert Storm; Zahi A Fayad; Willem J M Mulder
Journal:  ACS Nano       Date:  2011-05-25       Impact factor: 15.881

7.  Engineered synthetic polymer nanoparticles as IgG affinity ligands.

Authors:  Shih-Hui Lee; Yu Hoshino; Arlo Randall; Zhiyang Zeng; Piere Baldi; Ruey-An Doong; Kenneth J Shea
Journal:  J Am Chem Soc       Date:  2012-09-17       Impact factor: 15.419

Review 8.  Image-guided interventional therapy for cancer with radiotherapeutic nanoparticles.

Authors:  William T Phillips; Ande Bao; Andrew J Brenner; Beth A Goins
Journal:  Adv Drug Deliv Rev       Date:  2014-07-09       Impact factor: 15.470

Review 9.  Multifunctional nanoparticles for brain tumor imaging and therapy.

Authors:  Yu Cheng; Ramin A Morshed; Brenda Auffinger; Alex L Tobias; Maciej S Lesniak
Journal:  Adv Drug Deliv Rev       Date:  2013-09-20       Impact factor: 15.470

10.  Theranostic magnetic core-plasmonic shell star shape nanoparticle for the isolation of targeted rare tumor cells from whole blood, fluorescence imaging, and photothermal destruction of cancer.

Authors:  Zhen Fan; Dulal Senapati; Anant Kumar Singh; Paresh Chandra Ray
Journal:  Mol Pharm       Date:  2012-11-07       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.